Microencapsulation techniques for developing cannabidiol formulations: a review
AG Garro, S Ravetti, SG Brignone, A Luna… - Therapeutic …, 2024 - Taylor & Francis
Cannabidiol (CBD), extracted from Cannabis sativa L., holds therapeutic promise without
inducing psychoactive effects seen with Δ9-tetrahydrocannabinol. Its interaction with the …
inducing psychoactive effects seen with Δ9-tetrahydrocannabinol. Its interaction with the …
Enhanced oral bioavailability and in vitro evaluation of cannabidiol camel milk-derived exosome formulation in resistant MDA-MB-231 and MDA-MB-468 breast …
The potential of camel milk-derived exosomes (CMDE) to enhance the bioavailability of
Cannabidiol (CBD) was investigated. CBD-CMDE formulation was prepared using an …
Cannabidiol (CBD) was investigated. CBD-CMDE formulation was prepared using an …
CBD-Loaded Nanostructured Lipid Carriers: Optimization, Characterization, and Stability
Y Xie, P Li, D Fu, F Yang, X Sui, B Huang, J Liu… - ACS …, 2024 - ACS Publications
Cannabidiol (CBD) has demonstrated its potential to enhance depression treatment through
various biological pathways. However, the application potential of CBD is significantly …
various biological pathways. However, the application potential of CBD is significantly …
Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review
A Di Salvo, E Chiaradia, M Sforna… - Veterinary Research …, 2024 - Springer
Since the discovery of the endocannabinoid system and due to the empirical evidence of the
therapeutic effects on several illnesses both in humans and animals that follow the …
therapeutic effects on several illnesses both in humans and animals that follow the …
Responsive Supramolecular Nanomicelles Formed through Self-Assembly of Acyclic Cucurbit[n]uril for Targeted Drug Delivery to Cancer Cells
Y Li, Q Liu, J Ding, J Zou, B Yang - Molecular Pharmaceutics, 2024 - ACS Publications
The supramolecular drug delivery systems (SDDSs) based on host–guest recognition
through noncovalent interactions, capable of responsive behavior and dynamic switching to …
through noncovalent interactions, capable of responsive behavior and dynamic switching to …
[HTML][HTML] Selected phytocannabinoids inhibit SN-38-and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro
Irinotecan use is linked to the development of gastrointestinal toxicity and inflammation, or
gastrointestinal mucositis. Selected phytocannabinoids have been ascribed anti …
gastrointestinal mucositis. Selected phytocannabinoids have been ascribed anti …
Characterization of cannabidiol-rich hemp extract containing mucoadhesive gels: Nonaqueous versus aqueous based formulations
P Tabboon, E Limpongsa, S Tuntiyasawasdikul… - Journal of Drug Delivery …, 2025 - Elsevier
This work aimed to investigate a mucoadhesive gel containing cannabidiol (CBD)-rich hemp
extract (67% CBD) for oromucosal delivery of CBD. Various carbomer gels (nonaqueous …
extract (67% CBD) for oromucosal delivery of CBD. Various carbomer gels (nonaqueous …
Safety assessment on CBD-rich hemp extract in sub-chronic cross-sex study with rats
J Dehner, HH Polanska, K Petrlakova… - Toxicology and Applied …, 2025 - Elsevier
Cannabidiol (CBD) is a phytocannabinoid from Cannabis sativa L., in which there is
currently growing interest for medicinal use. Here, we focused on the safety and …
currently growing interest for medicinal use. Here, we focused on the safety and …
[HTML][HTML] Selection of In Vivo Relevant Dissolution Test Parameters for the Development of Cannabidiol Formulations with Enhanced Oral Bioavailability
N Koch, Q Bourcy, O Jennotte, P Chiap, A Lechanteur… - Pharmaceutics, 2025 - mdpi.com
Background: Cannabidiol (CBD) shows interesting therapeutic properties but has yet to
demonstrate its full potential in clinical trials partly due to its low solubility in physiologic …
demonstrate its full potential in clinical trials partly due to its low solubility in physiologic …
Chronic oral dosing of cannabidiol and cannabidiolic acid full-spectrum hemp oil extracts has no adverse effects in horses: a pharmacokinetic and safety study
TC Wang, JJ Wakshlag, MC Jager… - American Journal of …, 2025 - Am Vet Med Assoc
OBJECTIVE To compare the pharmacokinetics of cannabidiol (CBD) and cannabidiolic acid
(CBDA) in horses and to evaluate the safety of their chronic administration. METHODS CBD …
(CBDA) in horses and to evaluate the safety of their chronic administration. METHODS CBD …